CN102755517A - Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof - Google Patents
Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof Download PDFInfo
- Publication number
- CN102755517A CN102755517A CN2012102471363A CN201210247136A CN102755517A CN 102755517 A CN102755517 A CN 102755517A CN 2012102471363 A CN2012102471363 A CN 2012102471363A CN 201210247136 A CN201210247136 A CN 201210247136A CN 102755517 A CN102755517 A CN 102755517A
- Authority
- CN
- China
- Prior art keywords
- radix
- treatment
- paste
- chinese herbs
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title abstract description 20
- 206010003119 arrhythmia Diseases 0.000 title abstract description 14
- 230000006793 arrhythmia Effects 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims description 51
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 235000008216 herbs Nutrition 0.000 claims description 23
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 9
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000011866 long-term treatment Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 10
- 206010003658 Atrial Fibrillation Diseases 0.000 description 8
- 238000001467 acupuncture Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 6
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010049447 Tachyarrhythmia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 206010049765 Bradyarrhythmia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine plaster, particularly a traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof. The traditional Chinese medicine plaster for treating arrhythmia is applied onto the Neiguan acupoint and used for treating arrhythmia. The traditional Chinese medicine plaster for treating arrhythmia is prepared from the following components in percentage by mass by two different methods: 20-40% of angelica, 25-30% of cassia twig, 15-20% of radix ophiopogonis, 5-10% of mint and 15-20% of nard. The traditional Chinese medicine plaster for treating arrhythmia is medicated by acupoint application, can perform the two functions of continuous medication and continuous acupoint stimulation, and has fewer side effects, thereby being beneficial to long-term treatment and paroxysm prevention of arrhythmia. Both the two preparation methods provided by the invention have the advantages of simpleness, high operability and the like.
Description
Technical field
The present invention relates to a kind of Chinese herbs paste, be specifically related to ARR Chinese herbs paste of a kind of treatment and preparation method thereof, paste and give Neiguan acupoint, be used to control arrhythmia.
Background technology
Arrhythmia belongs to categories such as the traditional Chinese medical science " cardiopalmus ", " severe palpitation ", and modern medicine comprises tachyarrhythmia and bradyarrhythmia, comprise as the chamber of taking place frequently early, the room morning of taking place frequently, atrial fibrillation, chamber quiver, conduction block, bradycardia etc.Such disease presents the characteristics of the chronic course of disease, acute attack, requires SM, and partial function arrhythmia patient can not use western medicine, and therapies such as Chinese medicine, acupuncture have bigger clinical demand.
Traditional therapy comprises oral medicine, acupuncture and moxibustion therapy, and Western medicine is oral to have side effect such as Liver and kidney burden, proarrhythmia.Like atrial fibrillation therapy medicine amiodarone commonly used, have side effect such as hyperthyroidism, pulmonary fibrosis, abnormal liver function, rhythm of the heart equality treatment antiarrhythmic medicament has the ARR effect that causes.In the traditional Chinese medical herbal treatment, the acupuncture and moxibustion therapy curative effect is widely used, but the acupuncture and moxibustion therapy curative effect is difficult to lastingly, and inconvenient patient adheres to treatment.Therefore invent a kind of less side effect that both had, can play again and continue medication and two kinds of effects of lasting acupoint stimulation, the medicine that helps ARR long-term treatment and prevention seems particularly important.
Summary of the invention
For overcoming the defective of prior art; The object of the present invention is to provide the ARR Chinese herbs paste of a kind of treatment; Neiguan acupoint is given in subsides, is used to control arrhythmia, has both had less side effect; Can play again and continue medication and two kinds of effects of lasting acupoint stimulation, help ARR long-term treatment and prevention.
Another object of the present invention is to provide a kind of method for preparing of treating ARR Chinese herbs paste.
The technical scheme that is adopted for the present invention of realization above-mentioned purpose is following:
The ARR Chinese herbs paste of a kind of treatment, it is to process with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos, wherein the mass fraction of each component is respectively:
Radix Angelicae Sinensis 20-40%
Ramulus Cinnamomi 25-30%
Radix Ophiopogonis 15-20%
Herba Menthae 5-10%
Radix Et Rhizoma Nardostachyos 15-20%.
In the preferred scheme, the ARR Chinese herbs paste of described treatment is to process with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos, and wherein the mass fraction of each component is respectively:
Radix Angelicae Sinensis 30%
Ramulus Cinnamomi 28%
Radix Ophiopogonis 17%
Herba Menthae 10%
Radix Et Rhizoma Nardostachyos 15%.
The ARR Chinese herbs paste of treatment can adopt following several method preparation among the present invention:
A kind of method for preparing of treating ARR Chinese herbs paste, it may further comprise the steps
1) get Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos medicinal raw material in the formula ratio and use 6 times of weight in each reflux, extract, of 95% ethanol of medicinal raw material once respectively, filter, filtering residue reuse and each reflux, extract, of ethanol of 80% are once; Filter; Merge all filtratings, reclaim ethanol, get the thick paste I;
2) second extraction: each the composition residue after the said extracted adds 6 times of water gagings respectively and decocts 1-3 time, filters, and remerges filtrating and is condensed into the thick paste II;
3) molding: above-mentioned thick paste I, II are mixed, add glycerol, Carboxymethyl cellulose sodium, sorbitol mix homogeneously successively, fling to the thick shape of moisture to cream, obtain the thick paste III,, cut into the fritter paster in 50-70 ℃ of coating, packing.
In the step 3), the consumption of glycerol, Carboxymethyl cellulose sodium, sorbitol is respectively 0.5-2%, 0.1-1%, the 0.1-1% of thick paste I and thick paste II weight sum.In the preferable prescription, the consumption of glycerol, Carboxymethyl cellulose sodium, sorbitol is respectively 1%, 0.5%, 0.5% of a thick paste III weight.
In the step 3), said fritter paster is the long 2-3cm that is, wide is the paster of 2-3cm specification.
The method for preparing of the ARR Chinese herbs paste of another kind of treatment of the present invention, carry out according to following steps: according to formula ratio each composition is broken into medicated powder respectively, the fully mixing of back that sieves, subsequent use; Get mixed powder 5-10g, with ethanol 1-2ml and vinegar 1-2ml, the furnishing pasty state is split on the adhesive plaster that diameter is 4-6cm and processes paster.
The method for using that the present invention treats ARR Chinese herbs paste is: clean local skin earlier, the reuse finger is rubbing on the acupuncture point about l0s, with skin red heat degree of being; With nei guan point pad pasting face acupuncture point; Suitably afterburning pressurization 0.5min gets final product, and continues to stick 24h, sticks every other day 1 time.
Compare prior art; Beneficial effect of the present invention is: the present invention treats ARR Chinese herbs paste through the point application administration; Both can play and continue medication and two kinds of effects of lasting acupoint stimulation, less again side effect helps ARR long-term treatment and prevention outbreak.The ARR Chinese herbs paste of treatment of the present invention can be through two kinds of method preparations, and two kinds of method for preparinies wherein all have advantages such as simple workable.
Embodiment below in conjunction with concrete is done further explain to the present invention.
The specific embodiment
Embodiment 1-3
The ARR Chinese herbs paste of treatment among the embodiment 1-3, it is to process according to following steps with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos:
1) get Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos medicinal raw material in the formula ratio and use 6 times of weight in each reflux, extract, of 95% ethanol of medicinal raw material once respectively, filter, filtering residue reuse and each reflux, extract, of ethanol of 80% are once; Filter; Merge all filtratings, reclaim ethanol, get the thick paste I;
2) second extraction: each the composition residue after the said extracted adds 6 times of water gagings respectively and decocts 1-3 time, filters, and remerges filtrating and is condensed into the thick paste II;
3) molding: above-mentioned thick paste I, II are mixed, add glycerol, Carboxymethyl cellulose sodium, sorbitol mix homogeneously successively, fling to the thick shape of moisture to cream, obtain the thick paste III,, cut into the fritter paster in 50-70 ℃ of coating, packing.
In the step 3), the specification of the used sieve that sieves is the 80-120 order.
In the step 3), the consumption of glycerol, Carboxymethyl cellulose sodium, sorbitol is respectively thick paste I and thick paste II weight sum 0.5-2%, 0.1-1%, 0.1-1%.
Wherein the consumption of each component is seen table 1 in the specific embodiment:
Table 1
The component title | Embodiment 1 | Embodiment 2 | Embodiment 3 |
Radix Angelicae Sinensis | 20% | 40% | 30% |
Ramulus Cinnamomi | 30% | 25% | 28% |
Radix Ophiopogonis | 20% | 15% | 17% |
Herba Menthae | 10% | 5% | 10% |
Radix Et Rhizoma Nardostachyos | 20% | 15% | 15% |
Glycerol | 0.5% | 1% | 2% |
Carboxymethyl cellulose sodium | 0.1% | 0.5% | 1% |
Sorbitol | 0.1% | 0.5% | 1% |
Embodiment 4-6
Embodiment 4-6 treats ARR Chinese herbs paste, and it is to process according to following steps with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos: according to formula ratio each composition is broken into medicated powder respectively, and the fully mixing of back that sieves, subsequent use; Get mixed powder 5-10g, with ethanol 1-2ml and vinegar 1-2ml, the furnishing pasty state is split on the adhesive plaster that diameter is 4-6cm and processes paster.
Wherein the consumption of each component is seen table 2 in the specific embodiment:
Table 2
The component title | Embodiment 1 | Embodiment 2 | Embodiment 3 |
Radix Angelicae Sinensis | 20% | 40% | 30% |
Ramulus Cinnamomi | 30% | 25% | 28% |
Radix Ophiopogonis | 20% | 15% | 17% |
Herba Menthae | 10% | 5% | 10% |
Radix Et Rhizoma Nardostachyos | 20% | 15% | 15% |
Application implementation
207 routine tachyarrhythmia patients are in May, 2009 to 2010 year December Guangdong Provincial TCM Hospital heart center inpatient, and the table of random number method is divided into treatment group 104 example and matched group 103 examples.Male 65 examples in the treatment group, women 39 examples, year mean age (60 ± 10), artrial premature beat 12 examples, ventricular premature contraction 18 examples, paroxysmal supraventricular tachycardia 10 examples, atrial fibrillation 64 examples, expectorant stasis of blood resistance heart type 52 examples, type of insufficiency of heart-blood 27 examples, type of hyperactivity of fire caused by deficiency of YIN 8 examples, flaccidity of the heart-yang type 17 examples.Male 58 examples in the matched group, women 45 examples, year mean age (62 ± 10), artrial premature beat 23 examples, ventricular premature contraction 13 examples, paroxysmal supraventricular tachycardia 8 examples, atrial fibrillation 59 examples, expectorant stasis of blood resistance heart type 59 examples, type of insufficiency of heart-blood 19 examples, type of hyperactivity of fire caused by deficiency of YIN 10 examples, flaccidity of the heart-yang type 15 examples.Physical data such as two groups of patient's sexes, age, arrhythmia type, " cardiopalmus " type relatively, the difference not statistically significant (
P>0.05), has comparability.
The treatment group cleans local skin with the ARR Chinese herbs paste of treatment of the present invention according to elder generation; The reuse finger is rubbing on the acupuncture point about l0s, with skin red heat degree of being, with nei guan point pad pasting face acupuncture point; Suitably afterburning pressurization 0.5min gets final product; Continue to stick 24h, stick 1 time method every other day, treated for two weeks.
Matched group firmly begins to adopt simple medicine to treat for two weeks with treatment simultaneously, according to underlying diseases, selects Folium Digitalis Purpureae, B receptor blocking agent, calcium channel blocker or Ic class arrhythmia Propafenone, the treatment of III class anti-arrhythmic amiodarone.
The patient of treatment group and matched group is carried out the evaluation of heart rate, electrocardiogram, cardiopalmus symptom.
1. ECG curative effect standard
Formulate with reference to " clinical disease diagnosis is according to curing the improvement standard ".
Produce effects: electrocardiogram and 24 h cardiac monitorings show the more preceding minimizing of premature beat more than 75%, and Ventricular Rate is recovered normally or obviously to slow down, and the atrial fibrillation outbreak is controlled or controlled basically.
Effectively: electrocardiogram and 24 h cardiac monitorings are shown the more preceding minimizing of premature beat more than 50%, and Ventricular Rate slows down to some extent, and the atrial fibrillation outbreak persistent period shortens, and duration of seizure prolongs.
Invalid: electrocardiogram and 24 h cardiac monitorings are shown the more preceding minimizing of premature beat below 50%, Ventricular Rate no change or increase the weight of, no change or increase the weight of relatively before atrial fibrillation outbreak and the treatment.
According to above-mentioned standard respectively at row Electrocardioscopy before and after the treatment, before the course of treatment, the laggard action attitude Electrocardioscopy course of treatment, indexs such as premature beat number of times, Ventricular Rate, atrial fibrillation outbreak situation relatively.
2. cardiopalmus symptom criterion of therapeutical effect
Formulate with reference to " cardiopalmus " content in " disease of tcm diagnosis criterion of therapeutical effect ".With patient's cardiopalmus scoring is symptom score, according to therapeutic index (
n) judgement tcm syndrome total effects.Therapeutic index (
nIntegration before the)=(treatment-treatment back integration)/the preceding integration of treatment * 100%.
Recovery from illness
n>=70%.
Improvement 70%>
n>=30%.
Invalid
n<30%.
According to above-mentioned standard, in the treatment back patient's cardiopalmus symptom to be estimated, appraisal tool adopts 10 grades of marking scales of symptom to carry out sxemiquantitative and measures.Evaluation is undertaken by non-treatment operator, and front and back are same researcher, forbid adopting the inductivity language.
Adopt the SPSS13.0 statistical package to set up the data base, the arrangement of the line data of going forward side by side, check and statistical analysis.Relatively adopt X 2 test between the enumeration data group; Relatively adopt between the measurement data group
tCheck; Ranked data relatively adopt rank test between two groups.
Therapeutic outcome
1. two groups of supraventricular tachycardia patient treatment front and back changes in heart rate situation relatively
Visible by table 1, the heart rate situation compares before two groups of supraventricular tachycardia patient treatments, the difference not statistically significant (
P>0.05).Treatment group treatment back changes in heart rate and matched group comparison, difference have statistical significance (
P<0.05).
Changes in heart rate situation comparison before and after the table 4 liang group supraventricular tachycardia patient treatment (
±
s, inferior/min)
Annotate: with treatment is relatively preceding on the same group
1) P<0.05; Compare with matched group
2) P<0.05
2. two groups of patient's ECG curative effects relatively
Visible by table 5, treatment group treatment back electrocardiogram total effective rate is 87.5%, matched group be 75.7%, two group of comparing difference have statistical significance (
P>0.01), prompting treatment group treatment back electrocardiogram total effective rate is superior to matched group.
Table 5: two groups of patient's ECG curative effects relatively [
n(%)]
Group | Number n | Produce effects | Effectively | Invalid | Total effective rate/% |
The treatment group | 104 | 52(50.0%) | 39(37.5%) | 13(12.5%) | ?87.5 1) |
Matched group | 103 | 45(43.7%) | 33(32.0%) | 25(24.3%) | 75.7 |
Annotate: compare with matched group
1) P<0.01
3. two groups of patient's cardiopalmus symptoms alleviation situation immediately relatively
Visible by table 6, it is 89.4% that treatment group treatment back cardiopalmus symptom is alleviated total effective rate immediately, matched group be 79.6%, two group of comparing difference have statistical significance (
P>0.01), points out treatment group treatment back cardiopalmus symptom to alleviate total effective rate immediately and be superior to matched group.
Table 6: the comparison of two groups of patient's cardiopalmus symptoms alleviation situation immediately [
n(%)]
Group | Number n | Recovery from illness | Take a turn for the better | Invalid | Total effective rate/% |
The treatment group | 104 | 48(46.1%) | 45(43.3%) | 11(10.6%) | ?89.4 1) |
Matched group | 103 | 40(38.8%) | 42(40.8%) | 21(20.4%) | 79.6 |
Annotate: compare with matched group
1) P<0.01
This result of study shows, in Drug therapy simultaneously, adds with point application therapy more effectively to ARR control than healing with medicine merely, can control Ventricular Rate better, improves the cardiopalmus symptom, and is also effective in cure to Electrocardiographic improvement.
Claims (7)
1. the ARR Chinese herbs paste of treatment is characterized in that it is to process with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos, and wherein the mass fraction of each component is respectively:
Radix Angelicae Sinensis 20-40%
Ramulus Cinnamomi 25-30%
Radix Ophiopogonis 15-20%
Herba Menthae 5-10%
Radix Et Rhizoma Nardostachyos 15-20%.
2. the ARR Chinese herbs paste of treatment as claimed in claim 1 is characterized in that it is to process with Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos, and wherein the mass fraction of each component is respectively:
Radix Angelicae Sinensis 30%
Ramulus Cinnamomi 28%
Radix Ophiopogonis 17%
Herba Menthae 10%
Radix Et Rhizoma Nardostachyos 15%.
3. the method for preparing of the ARR Chinese herbs paste of treatment as claimed in claim 1, it is characterized in that: it may further comprise the steps
1) once extracts: get Radix Angelicae Sinensis, Ramulus Cinnamomi, Radix Ophiopogonis, Herba Menthae, Radix Et Rhizoma Nardostachyos medicinal raw material in the formula ratio and use 6 times of weight once respectively in each reflux, extract, of 95% ethanol of medicinal raw material; Filter; Filtering residue reuse and each reflux, extract, of ethanol of 80% are once filtered, and merge all filtratings; Reclaim ethanol, get the thick paste I;
2) second extraction: each the composition residue after the said extracted adds 6 times of water gagings respectively and decocts 1-3 time, filters, and remerges filtrating and is condensed into the thick paste II;
3) molding: above-mentioned thick paste I, II are mixed, add glycerol, Carboxymethyl cellulose sodium, sorbitol mix homogeneously successively, fling to the thick shape of moisture to cream, obtain the thick paste III, be applied on the cloth in 50-70 ℃, cut into the fritter paster, packing.
4. the method for preparing of the ARR Chinese herbs paste of treatment according to claim 3; It is characterized in that: in the step 3), the consumption of glycerol, Carboxymethyl cellulose sodium, sorbitol is respectively 0.5-2%, 0.1-1%, the 0.1-1% of thick paste I and II weight sum.
5. the method for preparing of the ARR Chinese herbs paste of treatment according to claim 4 is characterized in that: the consumption of glycerol, Carboxymethyl cellulose sodium, sorbitol is respectively 1%, 0.5%, 0.5% of thick paste I and an II weight sum in the step 3).
6. the method for preparing of the ARR Chinese herbs paste of treatment according to claim 3 is characterized in that: in the step 3), said fritter paster is the long 2-3cm that is, wide is the paster of 2-3cm specification.
7. the method for preparing of the ARR Chinese herbs paste of treatment as claimed in claim 1 is characterized in that the steps include: according to formula ratio each composition being broken into medicated powder respectively, and the fully mixing of back that sieves is subsequent use; Get mixed powder 5-10g, with ethanol 1-2ml and vinegar 1-2ml, the furnishing pasty state is split on the adhesive plaster that diameter is 4-6cm and processes paster.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210247136.3A CN102755517B (en) | 2012-07-17 | 2012-07-17 | Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210247136.3A CN102755517B (en) | 2012-07-17 | 2012-07-17 | Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102755517A true CN102755517A (en) | 2012-10-31 |
CN102755517B CN102755517B (en) | 2014-02-12 |
Family
ID=47050331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210247136.3A Expired - Fee Related CN102755517B (en) | 2012-07-17 | 2012-07-17 | Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102755517B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105902984A (en) * | 2016-05-29 | 2016-08-31 | 山东仁和堂药业有限公司 | Propafenone hydrochloride tablets and preparation method thereof |
CN106943489A (en) * | 2017-04-10 | 2017-07-14 | 牡丹江医学院 | A kind of Chinese medicine composition of General surgical treatment hemorrhoid and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513535A (en) * | 2003-08-14 | 2004-07-21 | 彭若宇 | Chinese medicinal preparation for treating coronarg heart disease arrhythmia and its manufacturing process |
CN101507810A (en) * | 2009-03-27 | 2009-08-19 | 刘玉梅 | Chinese patent medicine preparation capable of treating arrhythmia |
CN101658661A (en) * | 2008-08-28 | 2010-03-03 | 天津市中宝制药有限公司 | Chinese medicinal composition having effect of promoting blood circulation and removing blood stasis |
-
2012
- 2012-07-17 CN CN201210247136.3A patent/CN102755517B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513535A (en) * | 2003-08-14 | 2004-07-21 | 彭若宇 | Chinese medicinal preparation for treating coronarg heart disease arrhythmia and its manufacturing process |
CN101658661A (en) * | 2008-08-28 | 2010-03-03 | 天津市中宝制药有限公司 | Chinese medicinal composition having effect of promoting blood circulation and removing blood stasis |
CN101507810A (en) * | 2009-03-27 | 2009-08-19 | 刘玉梅 | Chinese patent medicine preparation capable of treating arrhythmia |
Non-Patent Citations (1)
Title |
---|
吴大真等: "《现代名中医冠心病治疗绝技》", 29 February 2004, 科学技术文献出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105902984A (en) * | 2016-05-29 | 2016-08-31 | 山东仁和堂药业有限公司 | Propafenone hydrochloride tablets and preparation method thereof |
CN106943489A (en) * | 2017-04-10 | 2017-07-14 | 牡丹江医学院 | A kind of Chinese medicine composition of General surgical treatment hemorrhoid and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102755517B (en) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114010751B9 (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue | |
CN104258350A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation | |
CN103479969B (en) | A kind of medicine for the treatment of manic-depressive psychosis and preparation method thereof | |
CN102755517B (en) | Traditional Chinese medicine plaster for treating arrhythmia and preparation methods thereof | |
CN100488558C (en) | Medicament for treating heart disease and preparation process thereof | |
CN102908513A (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
CN103520288A (en) | External drug for treating heart disease and vasculitis, and its application | |
CN102579804B (en) | Chinese medicine for treating stenocardia | |
CN105770399A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
CN105343277A (en) | Skin-nursing traditional Chinese medicine ointment for treating tinea versicolor and preparation method of skin-nursing traditional Chinese medicine ointment | |
CN105435196A (en) | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof | |
CN105477373B (en) | Chinese patent medicine for treating myocardial infarction and preparation method thereof | |
CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
CN104857393A (en) | Pharmaceutical preparation for treating arrhythmia | |
CN101983712A (en) | Novel medicament for treating coronary heart disease | |
CN112294901B (en) | Traditional Chinese medicine composition for treating supraventricular arrhythmia and preparation method and application thereof | |
CN105106786B (en) | The external medicine composition and its preparation and preparation method of a kind of Tongluo Shujin | |
CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
CN102552724A (en) | Chinese medicine composite for curing hypertension | |
CN105079394A (en) | Pharmaceutic preparation for treating arrhythmia | |
CN108310207B (en) | Pharmaceutical composition for treating heart failure and preparation method thereof | |
CN107213343A (en) | A kind of canker sore Chinese medicine ointment containing bletilla and preparation method thereof | |
CN114668817A (en) | Pharmaceutical formulation for treating arrhythmia and postoperative recovery of heart | |
CN103961603A (en) | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140212 |
|
CF01 | Termination of patent right due to non-payment of annual fee |